Cetus/Roche
Executive Summary
Firms are not involved in a patent dispute over development of interleukin-2 as was stated in April 10 issue, T&G-2. Cetus and Roche, in fact, signed a cross-licensing agreement for the biotech product on Dec. 22 ("The Pink Sheet" Jan. 2, T&G-5).
You may also be interested in...
Argenx’s Autoimmune Disease Blockbuster-In-Waiting Gets FDA Decision Date
The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.
Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature
In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: